The PRIME trial protocol: evaluating the impact of an intervention implemented in public health centres on management of malaria and health outcomes of children using a cluster-randomised design in Tororo, Uganda. by Staedke, Sarah G et al.
Staedke, SG; Chandler, CI; Diliberto, D; Maiteki-Sebuguzi, C; Nankya,
F; Webb, E; Dorsey, G; Kamya, MR (2013) The PRIME trial proto-
col: evaluating the impact of an intervention implemented in public
health centres on management of malaria and health outcomes of
children using a cluster-randomised design in Tororo, Uganda. Im-
plement Sci, 8 (1). p. 114. ISSN 1748-5908
Downloaded from: http://researchonline.lshtm.ac.uk/1366878/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
STUDY PROTOCOL Open Access
The PRIME trial protocol: evaluating the impact of
an intervention implemented in public health
centres on management of malaria and health
outcomes of children using a cluster-randomised
design in Tororo, Uganda
Sarah G Staedke1,2*, Clare IR Chandler3, Deborah DiLiberto1, Catherine Maiteki-Sebuguzi2, Florence Nankya2,
Emily Webb4, Grant Dorsey5 and Moses R Kamya2,6
Abstract
Background: In Africa, inadequate health services contribute to the lack of progress on malaria control. Evidence of
the impact of interventions to improve health services on population-level malaria indicators is needed. We are
conducting a cluster-randomised trial to assess whether a complex intervention delivered at public health centres in
Uganda improves health outcomes of children and treatment of malaria, as compared to the current standard of care.
Methods/Design: Twenty public health centres (level II and III) in Tororo district will be included; 10 will be randomly
assigned to the intervention and 10 to control. Clusters will include households located within 2 km of health centres.
The trial statistician will generate the random allocation sequence and assign clusters. Health centres will be stratified
by level, and restricted randomisation will be employed to ensure balance on cluster location and size. Allocation will
not be blinded. The intervention includes training in health centre management, fever case management with use of
rapid diagnostic tests (RDTs) for malaria, and patient-centered services, and provision of artemether-lumefantrine (AL)
and RDTs when stocks run low. The impact of the intervention on population-level health indicators will be assessed
through community surveys conducted at baseline in randomly selected children from each cluster, and repeated
annually for two years. The impact on individuals over time will be assessed in a cohort study of children recruited
from households randomly selected per cluster. The impact on health centres will be assessed using patient exit
interviews, monthly surveillance, and assessment of health worker knowledge and skills. The primary outcome is the
prevalence of anaemia (haemoglobin <11.0 g/dL) in individual children under five measured in the annual community
surveys. The primary analysis will be based on the cluster-level results.
Discussion: The PRIME trial findings will be supplemented by the PROCESS study, an evaluation of the process,
context, and wider impact of the PRIME intervention which will be conducted alongside the main trial, together
providing evidence of the health impact of a public sector intervention in Uganda.
Trial registration and funding: This trial is registered at Clinicaltrials.gov (NCT01024426) and is supported by the ACT
Consortium.
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Background
Malaria is a focus of Millennium Development Goal 4,
aiming to reduce the mortality rate in children under
five by two-thirds, between 1990 and 2015 [1]. In the
past decade, increased donor financing and widespread
scale-up of malaria control measures have substantially
reduced the malaria burden in several countries [2-7].
However, these findings have not been consistent across
Africa [8], and malaria-associated morbidity and mortal-
ity remains high in some countries, including Uganda
[9-11]. In 2010, the World Health Organization (WHO)
released new guidelines for malaria diagnosis and treat-
ment recommending that suspected cases be confirmed
by a parasitological test prior to treatment, when pos-
sible [12]. Although WHO’s call for universal diagnostic
testing combined with increased availability of rapid
diagnostic tests (RDTs) for malaria and artemisinin-
based combination therapies (ACTs) should translate
into improved malaria control, in many areas, health
system challenges prevent achieving this in practice
[1,13]. One of the main clinical challenges has been the
management of negative RDT results, and the need to
expand malaria training packages to include manage-
ment of non-malaria febrile illnesses [14,15]. A more
comprehensive approach to healthcare is called for to
improve management of malaria and other febrile ill-
nesses, and attract patients to seek care.
Systematic reviews of evaluations of training-based in-
terventions aiming to change health worker behavior and
improve quality of care have produced mixed results in
both developed [16-19], and developing countries [20].
Despite the emphasis on training, clinical quality of care
remains poor in many low-resource settings [21,22]. The
failure of many training-based programs to improve clin-
ical care reflects a wider acknowledgement of a gap be-
tween knowledge and practice of health workers. Further
research into how to support clinicians to improve per-
formance beyond didactic training is urgently needed.
In our formative research, we identified barriers and
aspirations for quality healthcare in Tororo and evalu-
ated these results with an aim to identify intervention
options that could be feasibly implemented, and might
have the greatest impact on health outcomes [22]. These
findings were considered in the context of reviews of the
literature on previous interventions and theory of behav-
ior change and adult learning, and were discussed with
stakeholders in Uganda. Using this information, we
designed an intervention that could be sustainable by
the Ministry of Health (MoH) and district partners in
Uganda, which aims to attract patients to seek care and
improve the quality of care delivered at public health
centres. The intervention has four components includ-
ing: training in-charges in health centre management;
training to health workers in fever case management
and use of RDTs; training health workers in patient-
centered services; and ensuring adequate supplies of
artemether-lumefantrine (AL) and RDTs. The manuals
for delivering the intervention are available online at
http://www.actconsortium.org/pages/resources-prime-
trainer-and-learner-manuals-110.html. The interven-
tion components are based on a theory that behavior
change would occur as a cognitive, emotional, and
social process, occurring in a community of practice
[23,24], and supported by physical resources.
Methods/Design
Objectives and hypotheses
1. To compare the impact of the PRIME intervention
with current standard of care on key population-
based indicators, including the prevalence of
anaemia in children under five (Table 1). We will
test the primary hypothesis that the prevalence of
anaemia will be lower in individual children under
five from clusters randomised to the intervention
than in children randomised to standard care. We
will also test the secondary hypothesis that the
prevalence of parasitaemia in children under five,
and children aged 5 to 15 years, from clusters that
are randomised to the intervention will be lower
than in children randomised to standard care.
2. To compare the impact of the PRIME intervention
with current standard of care on key longitudinal
indicators, including treatment incidence density, in
a prospectively followed cohort of children under
five. We will test the hypothesis that delivery of
antimalarial treatment via current care will result in
over-treatment and a higher incidence of
antimalarial treatment in individual children, than
antimalarial treatment delivered from health centres
randomised to the intervention, which should be
targeted to test-confirmed cases of malaria.
3. To compare the impact of the PRIME intervention
with current standard of care on key indicators of
case management for malaria and other illnesses,
including the risk of inappropriate antimalarial
treatment, in children under five treated at health
centres. We will test the hypothesis that the
intervention decreases inappropriate treatment with
ACTs, as measured by the proportion of individual
children under five with suspected malaria and a
negative RDT result that are inappropriately treated
with an ACT plus the proportion of children under
five with suspected malaria and a positive RDT result
that are not prescribed an ACT at each health centre.
We expect inappropriate treatment with ACTs to be
lower in the health centres randomised to the
intervention than in those in the standard care group.
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Study site and population
Tororo district, eastern Uganda, is an area of high mal-
aria transmission intensity (estimated entomologic in-
oculation rate of 562 infective bites per person-year)
[25]. Seven sub-counties will be included (Figure 1). The
study area is rural with limited infrastructure and
education levels [26]. Very few households in the study
area have electricity (1%). Health centres in the study
area are generally run by nurses or nursing assistants,
and most are understaffed. Infrastructure at the health
centres is also limited; most lack electricity and running
water. Prior to the trial, delivery of supplies, including
Table 1 Study objectives and populations
Objective Study population and sample size
1. To compare the impact of the PRIME intervention to current standard
of care on key population-based indicators, including the prevalence of
anaemia in children under five
Cross-sectional community surveys in children under five and aged 5 to
15 years randomly selected from households in each cluster (8,766
children total); surveys will be conducted at baseline and then annually
for two years (three surveys in total)
2. To compare the impact of the PRIME intervention to current standard
of care on key longitudinal indicators, including treatment incidence
density, in a prospectively followed cohort of children under five
Cohort of children under five recruited from 25 households randomly
selected from each cluster (500 total) and followed for approximately
18 months in total, 12 months following the implementation of the
intervention; all children of appropriate age from each household will be
eligible to participate
3. To compare the impact of the PRIME intervention to current standard
of care on key indicators of case management for malaria and other
illnesses, including the risk of inappropriate antimalarial treatment, in
children under five treated at health centres
Exit interviews in patients attending public health centres (20 HC IIs and IIIs)
in the study area (three surveys in total). In the first two surveys, including
10 patients per health facility (200 patients per survey). In the final survey,
including 50 patients per health facility (1,000 patients in survey, 1,400
patients overall)
Figure 1 PRIME study area, health centres, and clusters.
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AL, to health centres in the study area has typically been
unpredictable.
Cluster randomisation
Twenty public health centres and their surrounding clus-
ters will be included in the trial; 10 clusters will be ran-
domly assigned to the intervention and 10 to control. The
cluster-randomised design was selected because the inter-
vention will be implemented at health centres, while the
primary outcome will be measured at the community level.
Government-run health centres (levels HC II and HC III)
will be the unit of randomisation. Clusters will be defined
prior to randomisation using a census database, and will in-
clude households located within 2 km of the health centres.
Households will be excluded from our sampling frame if
they are ≥ 2 km from any health centre. If a household is
within 2 km of more than one health centre, the household
will be assigned to the cluster of the closest health centre.
Of 22 health centres in the study area, two pairs of
health centres have substantially overlapping catchment
areas; one facility from each pair will be randomly ex-
cluded. Health centres will be stratified by level, and be-
cause of uneven numbers of HC IIs and IIIs, one of the
HC IIIs without a laboratory will be ‘demoted’ and paired
with a HC II to ensure even numbers. Restricted random-
isation will be employed to ensure balance on geograph-
ical location and cluster size. The trial statistician will
generate the random allocation sequence using random
number generation in R (http://www.r-project.org/), and
will assign clusters to study arms. Study personnel will en-
roll clusters, and allocation will not be blinded.
Sensitisation and recruitment of health centres
Key stakeholders, including national and district officials
and community representatives, will be sensitised about
the study design, selection of health centres, objectives,
and procedures. Each health centre will be approached
individually to discuss study participation, after random-
isation. An information sheet will be used to describe
the study and procedures, which will emphasise that
study participation is voluntary and that health centres
may withdraw at any time. Health centre in-charges will
have an opportunity to ask questions and will be asked
to provide verbal consent to participate on behalf of
their health centre. Information about the trial will be
provided at any time throughout the trial period, along
with the opportunity to cease participation, in line with
ethical practice of ongoing consenting procedures.
PRIME intervention
Overview
The intervention is designed to stimulate behavior
change and build capacity through training of in-charges
and health workers using adult learning techniques, and
to ensure adequate supply of drugs and diagnostics at
public health centres. Training sessions will be led by
skilled trainers and health workers will be trained in two
groups to ensure that clinical work at the health centres
continues alongside the training. Training workshops
will be held in convenient locations for the participants,
and all costs will be covered and documented by the
project. Training packages will be delivered over ap-
proximately 8 to 10 weeks; support for AL and RDTs
will continue for the duration of the trial (Figure 2).
Training in health centre management
Training in health centre management (HCM) aims to
equip in-charges with key skills and tools required to ef-
fectively and efficiently manage their health centre. The
HCM training package includes three workshops—
financial management, supply management, and in-
formation management (http://www.actconsortium.
org/pages/resources-prime-trainer-and-learner-man-
uals-110.html). The workshops will incorporate
both didactic teaching and learner-centred activities
including interactive practical sessions. Each work-
shop will include a half-day session once a week for
three consecutive weeks.
Training in fever case management
Training will be provided by the Joint Uganda Malaria
Training Program (JUMP) team [27] using the RDT
training guidelines [28], and RDT job aide, which have
been adopted and implemented by Uganda’s MoH. The
training includes sessions on evaluating febrile patients,
performing and reading an RDT, management of pa-
tients based on RDT results, recognising and referring of
patients with severe illness, RDT storage and monitoring,
and infection prevention. Training will be conducted by
the JUMP team over two weeks; the first two days will
focus on theory, followed by on-site training at the health
centres the next week. Additional on-site support supervi-
sion will be provided by the JUMP team six weeks and six
months after the initial training, as part of the standard
JUMP training.
Training in patient-centred services
This training package aims to improve interpersonal in-
teractions between health workers and patients by help-
ing health workers to identify interpersonal challenges
and develop skills for communicating and interacting
with patients and colleagues. The Patient-Centered Ser-
vices (PCS) training package includes six workshops:
Introduction to PCS; Improving interactions with pa-
tients – Part 1; Improving interactions with patients –
Part 2; Building a positive work environment; Improving
the patient visit for health workers; and Improving the
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patient visit for support staff (http://www.actconsortium.
org/pages/resources-prime-trainer-and-learner-manuals-110.
html). The training includes self-observation activities to
be carried out by health workers prior to each session,
with an emphasis on building on individual and group ex-
periences in learning through interactive workshops. Each
workshop will include a half-day session led by a skilled
trainer once a week for six consecutive weeks.
Supply of AL and RDTs
The project will supplement the supply of AL and RDTs
for malaria to ensure adequate stocks of these key com-
modities. Through Uganda’s National Medical Stores
(NMS), health centres are supplied with standardised
‘kits’ of medical supplies and drugs, every two months. If
the provision of AL and RDTs by NMS is not adequate
to meet demand at health centres, or if the NMS supply
chain fails, the project will supply additional AL and
RDTs. We will attempt to supply the same brand of
RDTs provided by NMS (generally SD Bioline Pf, or SD
Bioline Pf/PAN, Standard Diagnostics, Inc.).
A health sub-district liaison officer will be recruited to
receive and process requisitions for AL and RDTs from
health centres, aiming to mimic the current district proce-
dures of direct delivery to health centres. The intervention
will use the standard health management information sys-
tems (HMIS) supply management tools and procedures,
which are included in the HCM training. Supply support
Figure 2 Trial timeline.
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via the liaison officer will begin as the training package is
rolled out, and will continue until the final community
survey is completed.
Standard care
Standard care will include services typically provided by
public health centres. No additional training will be pro-
vided to the in-charges or health workers stationed at
these health centres; and no support for staffing or sup-
plies will be provided beyond what is supplied by the
district and MoH.
Methods of evaluation
Cross-sectional community surveys
At baseline and then annually for two years, community
surveys will be conducted with 8,766 children, including
4,383 under-five and 4,383 aged 5 to 15 years, to assess
the impact of the intervention on key population-level
health indicators, including prevalence of anaemia
(Table 2). New populations of children will be selected
for each survey, which will include a structured ques-
tionnaire administered to the primary caregiver, and a
clinical and laboratory assessment of each participating
child.
Recruitment
A sampling frame for the surveys will be generated using
the census database. All households enumerated during
the census will be assigned a unique number. A random
sample of households with at least one child under fif-
teen years of age will be selected from each cluster to
generate a list of households to be approached. Three
separate lists will be generated prior to each survey from
the original census list.
Study personnel will conduct door-to-door recruit-
ment. When a household with at least one child of ap-
propriate age is identified, study personnel will describe
Table 2 Primary and secondary outcomes
Outcomes Indicator
Objective 1: Cross-sectional community surveys
Prevalence of anaemia Proportion of Hb measurements <11.0 g/dL.
Anaemia will be classified according to
severity: mild (Hb 8.0 – 10.9), moderate
(Hb 5.0 – 7.9), severe (Hb <5.0).
Prevalence of
parasitaemia
Proportion of thick blood smears that are
positive for asexual parasites
Prevalence of
gametocytaemia
Proportion of thick blood smears that are
positive for gametocytes
All-cause mortality Probability of dying between birth and five
years of age, expressed per 1,000 live births
Objective 2: Cohort study
Antimalarial treatment
incidence density
Number of antimalarial treatments given for
fever/malaria over the period of follow-up
Incidence of illness
episodes
Episode of illness as reported by primary
caregiver
Incidence of febrile
episodes
Episode of illness associated with fever as
reported by primary caregiver
Prompt effective
treatment of fever
Proportion of children with fever treated
within 24 hours of onset of symptoms with
an ACT
Prompt effective
treatment of malaria
Proportion of children with malaria
(confirmed by a parasitological test) treated
within 24 hours of onset of symptoms with
an ACT
Incidence of serious
adverse events
Any experience that results in death, life-
threatening experience, hospitalisation,
persistent or significant disability or
incapacity, or specific medical or surgical
intervention to prevent one of the other
serious outcomes
Antibiotic treatment
incidence density
Number of antibiotic treatments given for
fever/bacterial illnesses over the period of
follow-up
Objective 3: Health facilities
Patient exit interviews
Inappropriate treatment
of malaria
Proportion of children under five with
suspected malaria and a negative RDT result
who are inappropriately given an ACT +
Proportion of children under five with
suspected malaria and a positive RDT result
who are not prescribed an ACT
Appropriate treatment of
malaria
Proportion of children under five with
suspected malaria and a positive RDT result
who are appropriately given an ACT +
Proportion of children under five with
suspected malaria and a negative RDT result
who are not prescribed an ACT
Inappropriate treatment
of malaria
Proportion of children under five with
suspected malaria and a positive RDT result
who are inappropriately given a non-ACT
regimen
Patient satisfaction with
healthcare
Proportion of patients indicating they were
satisfied with care provided at the health
centre in exit interviews
Table 2 Primary and secondary outcomes (Continued)
Health facility surveillance
Patient attendance Total number of patients attending health
facilities and their characteristics, including
age, gender, village of residence, and
diagnosis
Gaps in staffing
requirements
Required positions, as indicated by the MoH
staffing norms policy, which are unfilled for
greater than one month
Stock-outs of ACTs Days per month that AL supplied by NMS via
the district is not available
Health worker knowledge questionnaire
Knowledge
questionnaire scores
Proportion of questions answered correctly
following training in fever case management
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the purpose of the study in the appropriate language (usu-
ally Japadhola, Luganda or Swahili) with parent(s) or guard-
ian(s), and proceed with screening (Table 3). One child
under five and one child aged 5 to 15 years will be eligible
for participation from each household. If more than one
child of appropriate age resides in the household, study
personnel will record the gender and ages of all children
under five and all children between the ages of 5 to 15 years,
and one child from each age category will be randomly se-
lected for participation using pre-defined guidelines.
Survey procedures
Primary caregivers will be surveyed to gather informa-
tion about bednet use and management of fever within
the last two weeks in any child under the primary care-
giver’s care. In the final survey, all women of child-
bearing age (13 to 49 years) in the household will be
asked to provide birth histories, which will allow us to
estimate all-cause mortality in children under five.
In each survey, participating children will undergo a
brief history and physical examination, including meas-
urement of temperature, weight, mid-upper arm circumfer-
ence, and spleen size. Blood will be collected by fingerprick
for thick blood smear and haemoglobin (all surveys), and
for storage on filter paper for future molecular testing
(baseline survey only).
Sample size estimates
The primary outcome for community surveys, and the
overall trial, is the prevalence of anaemia (haemoglo-
bin <11.0 g/dL) in children under five (Table 2). Children
under five will be sampled from each study cluster in pro-
portion to the total cluster size, with a planned harmonic
mean of 200 children per cluster. Using methods for a
stratified, cluster-randomised design [29], and assuming a
prevalence of anaemia of 65% at baseline [30], with a coef-
ficient of variation (k) between clusters of 0.2, this sample
size will allow us to detect an absolute difference in
anaemia prevalence between study arms of 17% (or more)
with 80% power at a 5% significance level. If we assume
that the clusters are more homogeneous (k = 0.1), then a
difference of 10% (or more) can be detected.
Prevalence of parasitaemia is a secondary outcome of
the community surveys (Table 2). In children aged 5 to
15 years, the prevalence of parasitaemia is estimated to
be 60% at baseline [30]. Based on this, and assuming k =
0.2, we estimate that a harmonic mean of 200 children
aged 5 to 15 years surveyed in each cluster will allow us
to detect an absolute difference in the prevalence of
parasitaemia between study arms of 16%, at a 5% signifi-
cance level with 80% power.
We had originally planned to recruit 200 children under
five and 200 children aged 5 to 15 years from each cluster
for the community surveys. However, upon completing
the census, we discovered that the population of three
clusters was smaller than expected. To adjust for the vari-
ability in population size between the clusters, we opted
to weight the target sample size for the community survey
according to the total population of each cluster to
achieve a harmonic mean of 200 for each age category,
resulting in different sample sizes for each cluster.
Cohort study
A cohort of children under five will be enrolled from 25
households randomly selected from each cluster, for a
total of 500 households, to assess the impact of the inter-
vention on key longitudinal health indicators, including
antimalarial treatment incidence density (Table 2). The
cohort will be dynamic, and all children who are born, or
move into, a participating household will be eligible for
recruitment. Assessments will include clinical and
laboratory evaluations, household surveys, and monthly
household visits to gather information on management of
illnesses. Participants will be followed for approximately
18 months in total, the equivalent of approximately
12 months following implementation of the intervention.
Table 3 Selection criteria for community surveys, cohort study, and patient exit interviews
Study component Inclusion criteria Exclusion criteria
Cross-sectional community
survey
1) age <15 years 1) inability to locate the child
1) agreement of parents or guardians to provide informed
consent
2) agreement of a child aged 8 years or older to provide assent
Cohort study 1) age <5 years 1) intention to move during the follow-up
period
1) fagreement of parents or guardians to provide informed
consent
1) current enrollment in another research
study
Patient exit interviews 1) age <5 years None
2) agreement of parents or guardians to provide informed
consent
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Recruitment
A separate list of households to be approached for re-
cruitment into the cohort study will be generated from
the census database using the same methods as de-
scribed for the community surveys. Study personnel will
conduct door-to-door recruitment. When a household
with at least one child of appropriate age is identified,
study personnel will briefly describe the purpose of the
study. If the parents (or guardians) are interested, a
screening appointment will be scheduled. All children of
appropriate age from a single household will be eligible
for evaluation for study enrollment. The final clinical
screening activities will be conducted at a study clinic.
Children who meet the eligibility criteria (Table 3) will
undergo a clinical and laboratory evaluation. Height,
weight, and temperature will be measured, and spleen
size will be evaluated. Blood will be collected by finger
prick for thick blood smear, haemoglobin, and for stor-
age on filter paper for future molecular testing.
Study procedures
Clinical and laboratory evaluations of cohort participants
will be repeated every six months. Following enrollment,
or within two weeks period from enrollment, a house-
hold survey will be administered. Primary caregivers will
be asked to complete a survey questionnaire (similar to
that administered to in the community survey) to gather
information about bednet use and management of febrile
children. The household survey will then be repeated ap-
proximately 12 months after enrollment.
Primary caregivers will be asked to keep a diary of
health of study participants for the duration of follow-up.
The diaries will be based on instruments previously devel-
oped and validated in studies in Uganda and elsewhere in
Africa [31,32]. The diaries have been developed by a
Ugandan artist with input from the community, and will
be used to collect information on clinical symptoms and
healthcare expenditures. Households will be visited by
study personnel every two weeks during the first two
months, and then monthly, to collect completed diaries.
At each monthly visit, questionnaires will also be ad-
ministered to gather additional data on the health of par-
ticipants, management of any illnesses, and healthcare
expenditures. The information collected in the diaries and
the questionnaires will be complementary. Small incen-
tives (including sugar, soap, or washing powder) will also
be provided to each household during the monthly visit.
Adverse event monitoring
Adverse events will be monitored in the cohort study.
Data on serious adverse events (SAEs) and suspected ad-
verse drug reactions will be collected retrospectively
during the monthly household visits. Reports of SAEs that
are classified as at least ‘possibly’ related to administration
of AL, and reports of all suspected unexpected serious
adverse reactions (SUSARs) will be submitted to the
institutional review boards (IRBs) according to their
guidelines for expedited reporting. All serious adverse
event reports and summary reports of suspected adverse
drug reactions will be submitted to the IRBs, the Data and
Safety Monitoring Board, and the ACT Consortium Drug
Safety Register annually.
Sample size estimates
The primary outcome for the cohort study will be treat-
ment incidence density among children under five,
which is assumed to be 2.5 treatments per year at base-
line (Table 2). We conservatively estimate that at any
one time the average number of children under five per
household will be at least 1.6. Given this, 250 house-
holds, and at least 400 children at any one time, will be
available in each intervention group. Since the cohort is
dynamic, no allowance for losses to follow-up is re-
quired. Assuming that that treatment incidence re-
mains constant in the standard care arm at 2.5 per year
and k = 0.2, a total of 400 child-years of follow-up per
arm (40 child-years per cluster) will allow us to detect a
difference of one treatment per year between the two
interventions at the 5% significance level with 80%
power.
Patient exit interviews
Exit interviews will be conducted with caregivers of chil-
dren under five at all health centres to assess the impact
of the intervention on malaria case management (Table 2).
Three rounds of surveys are planned.
Recruitment
Children and their caregivers will be approached by
study personnel as they are leaving health centres. When
a caregiver with a child of appropriate age is identified,
study personnel will briefly describe the purpose of the
study, and review the selection criteria (Table 3). All
children of the same caregiver will be eligible to partici-
pate if of the appropriate age and seen by a health
worker at the health centre.
Study procedures
Caregivers will be interviewed using a standardised
questionnaire to gather information about the purpose
of the visit, presenting complaint, the child’s symptoms,
whether a RDT or blood smear was done, the diagnosis
given, medications prescribed, and medications received.
Additional information about the satisfaction of the
caregiver with the visit to the facility will also be
obtained.
A clinical evaluation of the child will also be performed
by a study physician as part of the exit interview. If the
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child has a temperature of ≥38.0°C or a history of fever
in the past 48 hours, a fingerprick blood sample will be
obtained to perform a RDT. Febrile children will be
treated with paracetamol as appropriate. The results of
the RDTs performed by the study personnel will be com-
pared to the results of RDTs performed by health facility
staff, where possible. Children with a positive RDT and no
evidence of severe malaria, who have not been prescribed
or received an ACT, will be given AL. Children with a
positive RDT and evidence of danger signs of severe dis-
ease will be referred to an appropriate facility for further
evaluation and treatment, regardless of the medicine
prescribed.
Sample size estimates
In the first two surveys, 10 patients will be selected by
convenience sampling from each facility to participate in
the interviews (200 total per survey). In the final survey,
50 patients will be recruited to participate (1,000 total in
survey). In total, 1,400 patients will participate in the
interviews.
The primary outcome for the patient exit interviews is
inappropriate treatment of malaria at health centres in
children under five, based on the result of a RDT
performed by the PRIME team (Table 2). The hypothesis
is that the proportion of children inappropriately treated
with an ACT will be lower in intervention health centres
compared to those in the standard care. In the original
sample size calculations (for rounds one and two), we
assumed this proportion to be 50% in the standard care
group. Thus, interviewing 10 children and their care-
givers in each of the 20 clusters would give 80% power
to detect an absolute difference in the proportion in-
appropriately treated for malaria between the two inter-
vention arms of 24% (or more) at the 5% significance
level, assuming a coefficient of variation between clus-
ters of 0.2 and allowing for the stratified design.
Although the original sample size calculations were
based on the assumption that inappropriate treatment
for malaria in the standard care group would be 50%,
preliminary estimates suggest that only 35% of children
in the standard care health centres have been inappro-
priately treated. Thus, for the final round of patient exit
interviews, the sample size calculations have been re-
vised. Assuming the proportion of children inappropri-
ately treated to be 35% in the standard care arm with
k = 0.2, interviewing 50 children and their caregivers in
each of the 20 clusters will give 80% power to detect
an absolute difference of 12% (or more) at the 5% sig-
nificance level.
Health centre surveillance
Surveillance activities will be conducted at all health
centres initially every month, to collect information
about patient attendance, drug stocks, staffing, and
health centre costs from all centres. After the first year,
data will be collected every two to three months. Data
will be collected using a modified version of the HMIS
outpatient department (OPD) register, developed in col-
laboration with the MoH, and the drug stock card. In
addition, the in-charge will be interviewed to gather in-
formation on factors affecting health centre operations.
Health worker knowledge questionnaires and skills
assessment
Health workers at all participating health centres will be
assessed about their knowledge of fever case manage-
ment soon after the implementation of the intervention.
The knowledge questionnaire includes structured ques-
tions allowing for open-ended answers to assess the
health workers’ knowledge about malaria transmission,
symptoms, diagnosis, and treatment, and etiology of
non-malaria fevers. Additional assessment of health
worker knowledge will be carried out using the pre- and
post-training questionnaires administered by the JUMP
team in their training on fever case management at ap-
proximately one year after the implementation of the
intervention. Approximately two years after implementa-
tion of the intervention, assessment of health worker
knowledge, and skills for performing RDTs will be
conducted. Additional information about prior training
on use of RDTs will be gathered, and health workers will
be observed performing an RDT and managing a child
with suspected malaria.
Management of ill children
In the community surveys, cohort study, and patient
exit interviews, children who are reported to have been
febrile in the past 48 hours, or who have a temperature
of ≥38.0°C, will have an RDT performed (SD Bioline Pf/
PAN, Standard Diagnostics, Inc.). Febrile children will
be treated with paracetamol as appropriate. Children
with a positive RDT and no evidence of severe malaria
will be treated with AL, if not already on appropriate
treatment. Children with a positive RDT and evidence
of danger signs of severe disease will be referred for fur-
ther evaluation and treatment. Any child with haemoglo-
bin <5.0 g/dL, or other concerning clinical symptoms will
be referred for further management as appropriate.
Laboratory procedures
Microscopy
Thick blood smears will be stained with 2% Giemsa for
30 minutes and read by experienced laboratory technol-
ogists who are not involved in direct participant care.
For the cohort study and first community survey, para-
site densities will be calculated by counting the number
of asexual parasites per 200 leukocytes (or per 500
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leukocytes, if the count is <10 asexual parasites/200 leu-
kocytes), assuming a leukocyte count of 8,000/μl. A
blood smear will be considered negative when the exam-
ination of 100 high power fields does not reveal asexual
parasites. For the second and final community survey,
thick blood smears will be read only for presence or ab-
sence of asexual parasites, parasite density will not be
determined. Gametocytaemia will also be determined
from thick smears. For quality control, all slides will be
read by a second microscopist and a third reviewer will
settle any discrepant readings.
Haemoglobin measurement
Haemoglobin will be measured from fingerprick blood
samples using a portable spectrophotometer (HemoCue,
Anglom, Sweden).
Molecular studies
A filter paper sample will be collected each time a thick
blood smear is obtained in the baseline cross-sectional
survey and cohort study. Blood will be placed onto filter
paper in approximately 25 μl aliquots per blood spot
(four blood spots per sample). The samples will be la-
beled, air-dried, and stored at ambient temperature with
desiccant. Parasite DNA will subsequently be removed
from the filter paper and prepared for molecular analysis
using a chelex extraction method. Molecular studies
may include analyses of polymorphisms in parasite and/
or human genes for mutations that may impact on clin-
ical malaria, and genotyping of malaria parasites, and
will have no impact on the clinical management of study
participants.
Analytical plan
Analysis will be conducted at both the cluster level using
summary statistics from each cluster, and at the individ-
ual level. The primary analysis will be based on the
cluster-level results as this is expected to be more robust
when the number of clusters randomised is not large. A
two-stage approach based on cluster summaries will be
used to adjust for individual- and cluster-level covariates,
where appropriate.
Cross-sectional community surveys
Data from each community survey will be analysed sep-
arately. The crude prevalence of anaemia will be tabu-
lated for each cluster. A weighted average of the cluster
prevalences will also be calculated for comparison, with
the weights provided by the sample size for each cluster.
A risk ratio for the effect of the intervention will be cal-
culated directly from the cluster-based point estimates.
If necessary, a logarithmic transformation will be applied
to normalise cluster-specific prevalences before analyz-
ing the data. A stratified t-test will be used to compare
the means of the cluster-specific proportions, where the
within-stratum between-cluster variance will be esti-
mated as the residual mean square from a two-way ana-
lysis of variance of the log-prevalences on stratum and
treatment arm, including an interaction term. A 95%
confidence interval (CI) for the risk ratio, adjusting for
stratum, will be calculated from this variance using a
t-statistic with 16 degrees of freedom.
Adjustment for baseline imbalances between groups,
cluster-specific prevalence of anaemia collected at the
baseline community survey, and a priori individual-level
factors (age, gender, use of ITNs, and distance to the
health centre), will be conducted using a two-stage
process. At the first stage, a logistic regression model, in-
cluding terms for stratum and the covariates to be ad-
justed for, but excluding the intervention effect, will be
fitted to calculate cluster-specific predicted prevalences.
The ratio between the observed and predicted preva-
lence will be calculated (risk ratio-residuals). At the
second stage, methods described above for estimating
the 95% CI and performing a stratified t-test will be
conducted with the cluster-level prevalences replaced
with the covariate-adjusted ratio-residuals.
Cohort study
The number of events, child-years of follow-up, and cor-
responding treatment incidence rate will be tabulated by
cluster. For each study arm, the cluster-specific rates will
then be averaged to give a point estimate of the rate for
each intervention. Rate ratios for the effect of the inter-
vention on each outcome will then be calculated from
these point estimates. The distribution of cluster-specific
rates is likely to be skewed, therefore a logarithmic
transformation will be applied to normalise rates before
analysis. Methods for estimating the 95% CI and a for-
mal test of the null hypothesis that the rate ratio is equal
to one will be conducted. Adjusted analysis will be
conducted using the two-stage process described above,
except Poisson regression will be used to calculate pre-
dicted rates and rate ratio residuals. A priori individual-
level factors to be adjusted for are baseline anaemia, age,
gender, use of ITNs, and distance to the health centre.
Patient exit interviews
For each time point, the proportion of inappropriate
treatment of malaria will be tabulated by cluster, and the
cluster-specific mean proportions will be averaged to
give a point estimate of proportion of participants ap-
propriately treated with an ACT in each study arm. The
risk ratio for the impact of the intervention will then be
calculated. The two-way analysis of variance and strati-
fied t-test approach described above for the community
survey prevalence outcomes will then be applied to test
the null hypothesis that the risk ratio equals one and to
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derive a 95% CI for the risk ratio. Adjusted analyses will
also be performed to account for any baseline differ-
ences between the study arms, using the same two-stage
approach described above. A priori individual-level
factors to be adjusted for are age and gender.
Data management
A combination of approaches will be used to collect data
in this study, including use of paper forms, hand-held per-
sonal data assistants (PDAs), and tablet computers. Paper
versions will be used for screening forms; clinical record
forms for the baseline community survey and cohort
study; and interview questionnaires for the first two
rounds of patient exit interviews. Data entered onto paper
record forms will be double-entered into a computerised
database (Microsoft Access) to verify accuracy.
Data will be collected using questionnaires on PDAs
(Visual CE, Syware Inc) in the baseline community sur-
vey (survey questionnaire), the cohort study (first house-
hold survey, monthly questionnaires), and health centre
surveillance. Generally, field teams will move in pairs;
one team member will administer the questionnaire and
record answers on a PDA, while another will record an-
swers on a paper questionnaire. Data captured on PDAs
will be downloaded daily to a Microsoft Access data-
base. Data captured on paper record forms will be used
as back-up if synchronisation of the PDA to the
computerised database fails.
Tablet computers will be used to collect data for the
repeat community surveys, the second cohort household
survey, the final round of patient exit interviews, and the
final six months of health centre surveillance. Informa-
tion from the questionnaires and fields for entering re-
sults of biomarker testing will be programmed into the
tablets. Programming will include range, structure, and
internal consistency checks. Data from these devices will
be transferred at the end of every day to our core facility
and stored on a secure server. Microscopy results will be
recorded in a laboratory record book by lab technicians
and will be double-entered into a computerised database
(Microsoft Access) to verify accuracy.
Ethical approval
The trial has been approved by the Ugandan National
Council for Science and Technology (UNCST Ref HS
794), the Makerere University School of Medicine Re-
search & Ethics Committee (SOMREC Ref 2010–108),
The London School of Hygiene and Tropical Medicine
Ethics Committee (LSHTM Ref 5779), and the Univer-
sity of California San Francisco Committee on Human
Research (UCSF CHR Ref 006160). Sponsorship and in-
surance is provided by the LSHTM’s Clinical Trials Sub-
Committee (Ref QA292).
Informed consent
Study personnel will conduct informed consent discussions
with all potential participants emphasising that the participa-
tion in the study is voluntary and that participants have the
opportunity to withdraw from the study at any time without
consequence. All information sheets and consent forms will
be available in English, Japadhola, Luganda, and Swahili, and
will be verified for accuracy through back-translation. Con-
sent discussions will be conducted in the appropriate lan-
guage and a translator will be used if necessary.
Verbal consent will be sought from health centre in-
charges to participate in study, and to conduct evaluation
activities (patient exit interviews, surveillance, and health
worker knowledge and skills assessments) at their health
centre. For the baseline community survey and the cohort
study, written consent will be sought from parents (or
guardians) for their child to participate in a research study
and for the future use of biological specimens (filter paper
samples). For the repeat community surveys and the pa-
tient exit interviews, written consent will be sought for
study participation only, because no filter paper samples
will be collected. If the parent or guardian is unable to read
or write, their fingerprint will substitute for a signature,
and a signature from a witness to the informed consent
procedures will be obtained. Written assent to participate
in the community surveys will also be obtained from chil-
dren aged 8 years and older at the time of screening.
Trial status
The PRIME trial field work completed in July 2013. Data
cleaning and analysis of the final community survey, in-
cluding the primary outcome for the survey and the
overall trial, has not yet begun.
Discussion
The PRIME trial will provide evidence on the impact and
sustainability of an intervention to improve quality of
healthcare, as compared to the current standard of care
currently provided at public health centres, focusing on
health outcomes in children and appropriate treatment of
malaria. The PROCESS study, a mixed-methods evalu-
ation, is also being conducted alongside the main trial [33].
The PROCESS study was designed to further our under-
standing about why the PRIME intervention is effective, or
not. The PROCESS study includes an evaluation of the im-
plementation of the intervention activities; mechanisms of
change from the perspective of implementers, health
workers, community members, and key stakeholders; a
context evaluation to capture information on factors that
may affect the implementation of the intervention or out-
comes; and a limited impact evaluation to assess the wider
impact of the intervention beyond outcomes of the PRIME
trial. The results of the PRIME trial will be interpreted
alongside the findings of the PROCESS study.
Staedke et al. Implementation Science 2013, 8:114 Page 11 of 13
http://www.implementationscience.com/content/8/1/114
Abbreviations
ACT: Artemisinin-based combination therapy; AL: Artemether-lumefantrine;
HC: Health centre; HCM: Health centre management; HMIS: Health
management information systems; JUMP: Joint Uganda malaria program;
IRB: Institutional review board; LSHTM: London school of hygiene and
tropical medicine; MoH: Ministry of health; MU: Makerere university (Kampala,
Uganda); M&E: Monitoring and evaluation; NMS: National medical stores;
OPD: Out-patient department; PCS: Patient-centered services; PDA: Personal
data assistant; RDT: Rapid diagnostic test; SAE: Serious adverse event;
SOMREC: School of medicine research and ethical committee (Makerere
University); SUSAR: Suspected unexpected serious adverse reaction;
UCSF: University of California, San Francisco; UNCST: Uganda national council
of science and technology; WHO: World Health Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SGS, CIRC, GD, and MK conceived of the study. CIRC, DD and SGS developed
the intervention, with support from CMS and FN. SGS, DD, CMS, and FN
drafted the protocol with CIRC, and with statistical support from EW. All
authors reviewed the protocol and gave permission for publication.
Acknowledgements
We would like to thank Rita Kabuleta Luswata, Tema Kizito, Joaniter
Nankabirwa, Levi Mugenyi, Geoff Lavoy, and the administration of the
Infectious Disease Research Collaboration for all of their contributions. We
are also grateful to the ACT Consortium for all of their support and
guidance. This work was supported by the ACT Consortium through a grant
from the Bill and Melinda Gates Foundation to the London School of
Hygiene & Tropical Medicine (ITGBVG01). All authors are funded by the ACT
Consortium for this work. The funder played no role in the design of the
study design; in the collection, analysis and interpretation data; in the writing
of the report; or in the decision to submit the paper for publication.
Author details
1Department of Clinical Research, London School of Hygiene & Tropical
Medicine, Keppel Street, London WC1E 7HT, United Kingdom. 2Infectious
Disease Research Collaboration, PO Box 7475, Kampala, Uganda.
3Department of Global Health and Development, London School of Hygiene
& Tropical Medicine, 15-17 Tavistock Place, London WC1H 95H, United
Kingdom. 4Department of Infectious Disease Epidemiology, London School
of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United
Kingdom. 5Department of Medicine, University of California, San Francisco,
Box 0811, San Francisco, California 94143, USA. 6Department of Medicine,
Makerere University, Kampala, Uganda.
Received: 29 July 2013 Accepted: 19 September 2013
Published: 30 September 2013
References
1. Lozano R, Wang H, Foreman KJ, et al: Progress towards millennium
development goals 4 and 5 on maternal and child mortality: an updated
systematic analysis. Lancet 2011, 378:1139–1165.
2. Barnes KI, Durrheim DN, Little F, et al: Effect of artemether-lumefantrine
policy and improved vector control on malaria burden in KwaZulu-Natal,
South Africa. PLoS Med 2005, 2:e330.
3. Nyarango PM, Gebremeskel T, Mebrahtu G, et al: A steep decline of malaria
morbidity and mortality trends in Eritrea between 2000 and 2004: the
effect of combination of control methods. Malar J 2006, 5:33.
4. O'Meara WP, Bejon P, Mwangi TW, et al: Effect of a fall in malaria
transmission on morbidity and mortality in Kilifi, Kenya. Lancet 2008,
372:1555–1562.
5. Ceesay SJ, Casals-Pascual C, Erskine J, et al: Changes in malaria indices
between 1999 and 2007 in the Gambia: a retrospective analysis.
Lancet 2008, 372:1545–1554.
6. Otten M, Aregawi M, Were W, et al: Initial evidence of reduction of malaria
cases and deaths in Rwanda and Ethiopia due to rapid scale-up of
malaria prevention and treatment. Malar J 2009, 8:14.
7. Aregawi MW, Ali AS, Al-mafazy AW, et al: Reductions in malaria and
anaemia case and death burden at hospitals following scale-up of
malaria control in Zanzibar, 1999–2008. Malaria J 2011, 10:46.
8. O'Meara WP, Mangeni JN, Steketee R, et al: Changes in the burden of
malaria in sub-Saharan Africa. Lancet Infect Dis 2010, 10:545–555.
9. Okiro EA, Bitira D, Mbabazi G, et al: Increasing malaria hospital admissions
in Uganda between 1999 and 2009. BMC Med 2011, 9:37.
10. Yeka A, Gasasira A, Mpimbaza A, et al: Malaria in Uganda: challenges to
control on the long road to elimination: I. Epidemiology and current
control efforts. Acta Trop 2012, 121:184–195.
11. Talisuna A, Adibaku S, Dorsey G, et al: Malaria in Uganda: challenges to
control on the long road to elimination. II. The path forward. Acta Trop
2012, 121:196–201.
12. World Health Organization: Guidelines for the treatment of malaria 2010.
http://www.who.int/malaria/publications/atoz/9789241547925/en/index.
html.
13. Reich MR, Takemi K, Roberts MJ, et al: Global action on health systems: a
proposal for the Toyako G8 summit. Lancet 2008, 371:865–869.
14. Reyburn H, Mbakilwa H, Mwangi R, et al: Rapid diagnostic tests compared
with malaria microscopy for guiding outpatient treatment of febrile
illness in Tanzania: randomised trial. BMJ 2007, 334:403.
15. Asiimwe C, Kyabayinze DJ, Kyalisiima Z, et al: Early experiences on the
feasibility, acceptability, and use of malaria rapid diagnostic tests at
peripheral health centres in Uganda-insights into some barriers and
facilitators. Implement Sci 2012, 7:5.
16. Soumerai SB, McLaughlin TJ, Avorn J: Improving drug prescribing in
primary care: a critical analysis of the experimental literature. Milbank Q
1989, 67:268–317.
17. Oxman AD, Thomson MA, Davis DA, et al: No magic bullets: a systematic
review of 102 trials of interventions to improve professional practice.
CMAJ 1995, 153:1423–1431.
18. Davis DA, Thomson MA, Oxman AD, et al: Changing physician
performance A systematic review of the effect of continuing medical
education strategies. JAMA 1995, 274:700–705.
19. Grimshaw J, Shirran L, Thomas R, et al: Changing provider behaviour: an
overview of systematic reviews of interventions to promote
implementation of research findings by healthcare professionals. In
Getting research findings into practice. 2nd edition. Edited by Haines A,
Donald A. London: BMJ Books; 2002:29–68.
20. Smith LA, Jones C, Meek S, et al: Review: provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria: do we know what works? Am J Trop Med Hyg 2009,
80:326–335.
21. Rowe AK, de Savigny D, Lanata CF, et al: How can we achieve and
maintain high-quality performance of health workers in low-resource
settings? Lancet 2005, 366:1026–1035.
22. Chandler CI, Kizito J, Taaka L, et al: Aspirations for quality health care in
Uganda: how do we get there? Hum Resour Health 2013, 11:13.
23. Wenger E: Communities of practice. Learning, meaning, and identity. New
York: Cambridge University Press; 1998.
24. Mann KV: Theoretical perspectives in medical education: past experience
and future possibilities. Med Educ 2011, 45:60–68.
25. Okello PE WVANB, Byaruhanga AM, et al: Variation in malaria transmission
intensity in seven sites throughout Uganda. Am J Trop Med Hyg 2006,
75:219–225.
26. Staedke SG: Phase 1 report: Tororo District survey project. Characterizing the
population and local health services. 2010. http://www.actconsortium.org/
resources.php.
27. Ssekabira U, Bukirwa H, Hopkins H, et al: Improved malaria case
management after integrated team-based training of health care
workers in Uganda. Am J Trop Med Hyg 2008, 79:826–833.
28. National Malaria Control Program: User’s manual: Use of Rapid Diagnostic
Tests (RDTs) for malaria in fever case management in Uganda. Kampala,
Uganda: Ministry of Health, Republic of Uganda; 2009.
29. Hayes R, Bennett S: Simple sample size calculations for cluster-
randomized trials. Int J Epidemiol 1999, 28:319–326.
30. Pullan RL, Bukirwa H, Staedke SG, et al: Plasmodium infection and its risk
factors in eastern Uganda. Malar J 2010, 9:2.
31. Wiseman V, Conteh L, Matovu F: Using diaries to collect data in resource-
poor settings: questions on design and implementation. Health Policy
Plan 2005, 20:394–404.
Staedke et al. Implementation Science 2013, 8:114 Page 12 of 13
http://www.implementationscience.com/content/8/1/114
32. Staedke SG, Mwebaza N, Kamya MR, et al: Home management of malaria
with artemether-lumefantrine compared with standard care in urban
Ugandan children: a randomised controlled trial. Lancet 2009,
373:1623–1631.
33. Chandler CIR, Diliberto D, Nayiga S, et al: The PROCESS study: a protocol
to evaluate the implementation, mechanisms of effect and context of an
intervention to enhance public health centres in Tororo, Uganda.
Implementation Science 2013, 8:113.
doi:10.1186/1748-5908-8-114
Cite this article as: Staedke et al.: The PRIME trial protocol: evaluating
the impact of an intervention implemented in public health centres on
management of malaria and health outcomes of children using a
cluster-randomised design in Tororo, Uganda. Implementation Science
2013 8:114.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Staedke et al. Implementation Science 2013, 8:114 Page 13 of 13
http://www.implementationscience.com/content/8/1/114
